A high fidelity CRISPR/Cas12a based lateral flow biosensor for the detection of HPV16 and HPV18

Mukama, Omar; Yuan, Ting; He, Zhixu; Li, Zhiyuan; Habimana, Jean de Dieu; Hussain, Muzammal; Li, Wei; Yi, Zhijian; Liang, Qiongxin; Zeng, Lingwen

doi:10.1016/j.snb.2020.128119

Cited by 97 publications

(84 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In most of these platforms, a commercially available universal test strip, the HybriDetect-Universal Lateral Flow Assay Kit, was used. This dipstick was originally designed for qualitative or even quantitative rapid testing of proteins, antibodies or gene amplicons, but has been adapted to function in several LFA based CRISPR sensing methods ( Bai et al, 2019 ; Chang et al, 2019 ; Gootenberg et al, 2018 ; Kaminski et al, 2020 ; Mukama et al, 2020b ; Sullivan et al, 2019 ; Tsou et al, 2019 ). This platform offers a Streptavidine line as well as an antibody line that can capture anti-FITC coated AuNPs ( Fig.…”

Section: Crispr/cas Sensing In Poc Sensorsmentioning

confidence: 99%

Point-of-care CRISPR/Cas nucleic acid detection: Recent advances, challenges and opportunities

Dongen

Berendsen

Steenbergen

et al. 2020

Biosensors and Bioelectronics

287

191

View full text Add to dashboard Cite

With the trend of moving molecular tests from clinical laboratories to on-site testing, there is a need for nucleic acid based diagnostic tools combining the sensitivity, specificity and flexibility of established diagnostics with the ease, cost effectiveness and speed of isothermal amplification and detection methods. A promising new nucleic acid detection method is Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-associated nuclease (Cas)-based sensing. In this method Cas effector proteins are used as highly specific sequence recognition elements that can be combined with many different read-out methods for on-site point-of-care testing. This review covers the technical aspects of integrating CRISPR/Cas technology in miniaturized sensors for analysis on-site. We start with a short introduction to CRISPR/Cas systems and the different effector proteins and continue with reviewing the recent developments of integrating CRISPR sensing in miniaturized sensors for point-of-care applications. Finally, we discuss the challenges of point-of-care CRISPR sensing and describe future research perspectives.

show abstract

Section: Crispr/cas Sensing In Poc Sensorsmentioning

confidence: 99%

Point-of-care CRISPR/Cas nucleic acid detection: Recent advances, challenges and opportunities

Dongen

Berendsen

Steenbergen

et al. 2020

Biosensors and Bioelectronics

287

191

View full text Add to dashboard Cite

show abstract

“…SHERLOCK technique is a detection method which combines isothermal amplification with CRISPR-mediated detection [ [104] , [105] , [106] , [107] ], and the technology reduces reliance on equipment. At present, this method is often used for virus detection [ [108] , [109] , [110] ]. Moreover, the SHERLOCK technique can be used to detect SARS-COV-2 virus and has clinical applications [ 111 ].…”

Section: Detection Methodsmentioning

confidence: 99%

Current methods and prospects of coronavirus detection

Deng

Liu

et al. 2021

Talanta

View full text Add to dashboard Cite

“…10 A) HPV POCT screening reduced progression to different cancer and mortality. B) illustration of a CIALFB bioassay developed using CRISPR/Cas12a for the selective detection of HPV 18 and HPV 18 ( Mukama et al, 2020 ). C) A Zn-dopped MoS2 QD based ECL biosensor developed for detecting HPV-16 DNA ( Nie et al, 2020 ).…”

Section: Iomt-assisted Poc Biosensing For Infectious Diseasesmentioning

confidence: 99%

“…Mukama et al validated a novel fluorescence diagnostic biosensor ( Fig. 10 B) based on isothermal LAMP amplification and the trans cleavage property of CRISPR/Cas system, which allowed selective detection of HPV16 and HPV18 with the LOD of 3.1 amol (∼1.8 copies) ( Mukama et al, 2020 ). During detection, HPV sequence bind to a complementary capture oligo immobilized on the LFA test line that lead to reporter sequences free for cleavage.…”

Section: Iomt-assisted Poc Biosensing For Infectious Diseasesmentioning

confidence: 99%

Internet of medical things (IoMT)-integrated biosensors for point-of-care testing of infectious diseases

Jain

Nehra

Kumar

et al. 2021

Biosensors and Bioelectronics

258

155

View full text Add to dashboard Cite

On global scale, the current situation of pandemic is symptomatic of increased incidences of contagious diseases caused by pathogens. The faster spread of these diseases, in a moderately short timeframe, is threatening the overall population wellbeing and conceivably the economy. The inadequacy of conventional diagnostic tools in terms of time consuming and complex laboratory-based diagnosis process is a major challenge to medical care. In present era, the development of point-of-care testing (POCT) is in demand for fast detection of infectious diseases along with “on-site” results that are helpful in timely and early action for better treatment. In addition, POCT devices also play a crucial role in preventing the transmission of infectious diseases by offering real-time testing and lab quality microbial diagnosis within minutes. Timely diagnosis and further treatment optimization facilitate the containment of outbreaks of infectious diseases. Presently, efforts are being made to support such POCT by the technological development in the field of internet of medical things (IoMT). The IoMT offers wireless-based operation and connectivity of POCT devices with health expert and medical centre. In this review, the recently developed POC diagnostics integrated or future possibilities of integration with IoMT are discussed with focus on emerging and re-emerging infectious diseases like malaria, dengue fever, influenza A (H1N1), human papilloma virus (HPV), Ebola virus disease (EVD), Zika virus (ZIKV), and coronavirus (COVID-19). The IoMT-assisted POCT systems are capable enough to fill the gap between bioinformatics generation, big rapid analytics, and clinical validation. An optimized IoMT-assisted POCT will be useful in understanding the diseases progression, treatment decision, and evaluation of efficacy of prescribed therapy.

show abstract

A high fidelity CRISPR/Cas12a based lateral flow biosensor for the detection of HPV16 and HPV18

Cited by 97 publications

References 26 publications

Point-of-care CRISPR/Cas nucleic acid detection: Recent advances, challenges and opportunities

Point-of-care CRISPR/Cas nucleic acid detection: Recent advances, challenges and opportunities

Current methods and prospects of coronavirus detection

Internet of medical things (IoMT)-integrated biosensors for point-of-care testing of infectious diseases

Contact Info

Product

Resources

About